Alumis files corporate deck outlining precision TYK2 inhibitors
Alumis Inc. submitted an exhibit detailing its precision engineered TYK2 inhibitors and pipeline strategy. The presentation provides an overview of clinical plans regarding envudeucitinib and future therapies for immune-mediated diseases.
View filing at SEC.gov →